The Pain Registry for Epidemiological, Clinical, and interventional Studies and Innovation (PRECISION)

Registry overview and protocol for a propensity score-matched study of opioid prescribing in patients with low back pain

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Low back pain is the leading cause of disability worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as the first-line pharmacologic therapy for subacute or chronic low back pain, with opioids reserved for patients who fail on NSAIDs. CYP2D6, CYP2C9, and CYP2C19 genes have variants that place patients using analgesics at risk for adverse events. However, precision medicine based on pharmacogenetically informed prescribing is becoming more feasible as genotyping costs decline. This study aims to compare opioids vs NSAIDs in treating adults with subacute or chronic low back pain under the alternative models of usual care and precision medicine. Methods: An observational cohort study within the Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation (PRECISION) will be used to simulate a randomized controlled trial. Patients using opioids and NSAIDs will be optimally matched at baseline using propensity scores. A saliva sample will also be collected to determine patient genotypes for drug metabolism based on CYP2D6 (single-gene model) and CYP2D6, CYP2C9, and CYP2C19 (multigene model). Prescribing that is concordant with pharmacogenetically informed care under these models will be considered “low risk”, whereas discordant prescribing will be considered “high risk”. Primary outcomes will be assessed over 6 months using a Numerical Rating Scale for pain, the Roland-Morris Disability Questionnaire, and the Drug Adverse Events Index. Secondary outcomes will be assessed using quality-of-life measures. An estimated 600 patients will be enrolled to acquire at least 400 patients after attrition and allowing for unmatched patients. This will achieve a statistical power of at least 80% in detecting the effect sizes ranging from 0.35 (small–medium effect) to 0.69 (medium–large effect). Discussion: This PRECISION Pain Research Registry study builds on the concepts espoused in the Precision Medicine Initiative and addresses long-term goals established by the National Institutes of Health by assessing how precision medicine may prevent and treat chronic pain.

Original languageEnglish
Pages (from-to)1751-1760
Number of pages10
JournalJournal of Pain Research
Volume11
DOIs
StatePublished - 1 Jan 2018

Fingerprint

Propensity Score
Low Back Pain
Opioid Analgesics
Registries
Precision Medicine
Pain
Cytochrome P-450 CYP2D6
Anti-Inflammatory Agents
Pharmaceutical Preparations
National Institutes of Health (U.S.)
Clinical Studies
Drug-Related Side Effects and Adverse Reactions
Saliva
Chronic Pain
Genes
Observational Studies
Analgesics
Cohort Studies
Randomized Controlled Trials
Genotype

Keywords

  • Biopsychosocial model
  • Codeine
  • Low back pain
  • Nonsteroidal anti-inflammatory drugs
  • Opioids
  • PRECISION Pain Research Registry
  • Pharmacogenetics
  • Physical functioning
  • Precision medicine
  • Quality of life

Cite this

@article{9dd4799c80194d808e71ada98928c1d8,
title = "The Pain Registry for Epidemiological, Clinical, and interventional Studies and Innovation (PRECISION): Registry overview and protocol for a propensity score-matched study of opioid prescribing in patients with low back pain",
abstract = "Background: Low back pain is the leading cause of disability worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as the first-line pharmacologic therapy for subacute or chronic low back pain, with opioids reserved for patients who fail on NSAIDs. CYP2D6, CYP2C9, and CYP2C19 genes have variants that place patients using analgesics at risk for adverse events. However, precision medicine based on pharmacogenetically informed prescribing is becoming more feasible as genotyping costs decline. This study aims to compare opioids vs NSAIDs in treating adults with subacute or chronic low back pain under the alternative models of usual care and precision medicine. Methods: An observational cohort study within the Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation (PRECISION) will be used to simulate a randomized controlled trial. Patients using opioids and NSAIDs will be optimally matched at baseline using propensity scores. A saliva sample will also be collected to determine patient genotypes for drug metabolism based on CYP2D6 (single-gene model) and CYP2D6, CYP2C9, and CYP2C19 (multigene model). Prescribing that is concordant with pharmacogenetically informed care under these models will be considered “low risk”, whereas discordant prescribing will be considered “high risk”. Primary outcomes will be assessed over 6 months using a Numerical Rating Scale for pain, the Roland-Morris Disability Questionnaire, and the Drug Adverse Events Index. Secondary outcomes will be assessed using quality-of-life measures. An estimated 600 patients will be enrolled to acquire at least 400 patients after attrition and allowing for unmatched patients. This will achieve a statistical power of at least 80{\%} in detecting the effect sizes ranging from 0.35 (small–medium effect) to 0.69 (medium–large effect). Discussion: This PRECISION Pain Research Registry study builds on the concepts espoused in the Precision Medicine Initiative and addresses long-term goals established by the National Institutes of Health by assessing how precision medicine may prevent and treat chronic pain.",
keywords = "Biopsychosocial model, Codeine, Low back pain, Nonsteroidal anti-inflammatory drugs, Opioids, PRECISION Pain Research Registry, Pharmacogenetics, Physical functioning, Precision medicine, Quality of life",
author = "Licciardone, {John C.} and Gatchel, {Robert Joseph} and Phillips, {Nicole Ruth} and Subhash Aryal",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/JPR.S169275",
language = "English",
volume = "11",
pages = "1751--1760",
journal = "Journal of Pain Research",
issn = "1178-7090",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The Pain Registry for Epidemiological, Clinical, and interventional Studies and Innovation (PRECISION)

T2 - Registry overview and protocol for a propensity score-matched study of opioid prescribing in patients with low back pain

AU - Licciardone, John C.

AU - Gatchel, Robert Joseph

AU - Phillips, Nicole Ruth

AU - Aryal, Subhash

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Low back pain is the leading cause of disability worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as the first-line pharmacologic therapy for subacute or chronic low back pain, with opioids reserved for patients who fail on NSAIDs. CYP2D6, CYP2C9, and CYP2C19 genes have variants that place patients using analgesics at risk for adverse events. However, precision medicine based on pharmacogenetically informed prescribing is becoming more feasible as genotyping costs decline. This study aims to compare opioids vs NSAIDs in treating adults with subacute or chronic low back pain under the alternative models of usual care and precision medicine. Methods: An observational cohort study within the Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation (PRECISION) will be used to simulate a randomized controlled trial. Patients using opioids and NSAIDs will be optimally matched at baseline using propensity scores. A saliva sample will also be collected to determine patient genotypes for drug metabolism based on CYP2D6 (single-gene model) and CYP2D6, CYP2C9, and CYP2C19 (multigene model). Prescribing that is concordant with pharmacogenetically informed care under these models will be considered “low risk”, whereas discordant prescribing will be considered “high risk”. Primary outcomes will be assessed over 6 months using a Numerical Rating Scale for pain, the Roland-Morris Disability Questionnaire, and the Drug Adverse Events Index. Secondary outcomes will be assessed using quality-of-life measures. An estimated 600 patients will be enrolled to acquire at least 400 patients after attrition and allowing for unmatched patients. This will achieve a statistical power of at least 80% in detecting the effect sizes ranging from 0.35 (small–medium effect) to 0.69 (medium–large effect). Discussion: This PRECISION Pain Research Registry study builds on the concepts espoused in the Precision Medicine Initiative and addresses long-term goals established by the National Institutes of Health by assessing how precision medicine may prevent and treat chronic pain.

AB - Background: Low back pain is the leading cause of disability worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as the first-line pharmacologic therapy for subacute or chronic low back pain, with opioids reserved for patients who fail on NSAIDs. CYP2D6, CYP2C9, and CYP2C19 genes have variants that place patients using analgesics at risk for adverse events. However, precision medicine based on pharmacogenetically informed prescribing is becoming more feasible as genotyping costs decline. This study aims to compare opioids vs NSAIDs in treating adults with subacute or chronic low back pain under the alternative models of usual care and precision medicine. Methods: An observational cohort study within the Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation (PRECISION) will be used to simulate a randomized controlled trial. Patients using opioids and NSAIDs will be optimally matched at baseline using propensity scores. A saliva sample will also be collected to determine patient genotypes for drug metabolism based on CYP2D6 (single-gene model) and CYP2D6, CYP2C9, and CYP2C19 (multigene model). Prescribing that is concordant with pharmacogenetically informed care under these models will be considered “low risk”, whereas discordant prescribing will be considered “high risk”. Primary outcomes will be assessed over 6 months using a Numerical Rating Scale for pain, the Roland-Morris Disability Questionnaire, and the Drug Adverse Events Index. Secondary outcomes will be assessed using quality-of-life measures. An estimated 600 patients will be enrolled to acquire at least 400 patients after attrition and allowing for unmatched patients. This will achieve a statistical power of at least 80% in detecting the effect sizes ranging from 0.35 (small–medium effect) to 0.69 (medium–large effect). Discussion: This PRECISION Pain Research Registry study builds on the concepts espoused in the Precision Medicine Initiative and addresses long-term goals established by the National Institutes of Health by assessing how precision medicine may prevent and treat chronic pain.

KW - Biopsychosocial model

KW - Codeine

KW - Low back pain

KW - Nonsteroidal anti-inflammatory drugs

KW - Opioids

KW - PRECISION Pain Research Registry

KW - Pharmacogenetics

KW - Physical functioning

KW - Precision medicine

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85058806055&partnerID=8YFLogxK

U2 - 10.2147/JPR.S169275

DO - 10.2147/JPR.S169275

M3 - Article

VL - 11

SP - 1751

EP - 1760

JO - Journal of Pain Research

JF - Journal of Pain Research

SN - 1178-7090

ER -